Erratum to: High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers

“…We investigated the expression of MAGE‐A and NY‐ESO‐1 in invasive breast cancer, and found prevalent expression within the TN group. Previous reports have shown variable expression of MAGE‐A and NY‐ESO‐1, ranging between 17% and 74%, and between 2% and 40%, respectively, and the expression levels of both were higher in TNBC, which corroborates our findings. Taking advantage of the large pre‐existing dataset on experimental biomarkers in the QFU cohort, we found that the CTAs are expressed most prevalently in the TN tumours showing salient features of poor differentiation/primitive phenotype, proliferation, and genomic instability.…”

Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer

“…CTAs are involved in cellular proliferation, migration/motility, colonization, and cell division in normal germ cells, while in cancer cells, CTAs have been implicated in sustenance of growth, maintaining nutrient and oxygen supply through the activation of angiogenesis, evading apoptotic cell death, increase in tissue invasiveness and metastasis, and development of resistance to anti-cancer drugs [214]. In breast cancer, CTAs, such as MAGE-1, AKAP4, NY-BR-1, CTAG1, BAGE1, MAGE-A10, SP17, NY-ESO-1, and MAGE-A, were found to play important roles in activating cell proliferation, inhibition of apoptosis, and promoting tissue invasion and metastasis [5,[215][216][217][218][219][220][221][222]. The CTA, AKAP4, in particular seems to be an interesting candidate for a serum-based diagnostic test for the early detection and diagnosis of breast cancer [221].…”

“…The CTA, AKAP4, in particular seems to be an interesting candidate for a serum-based diagnostic test for the early detection and diagnosis of breast cancer [221]. SP17, MAGE-A, NY-ESO-1, and MAGE-A10 on the other hand were more specifically associated with TNBCs [216,218,219]. There is but little evidence that could link the occurrence of diabetes to the expression of the CTAs, which can then be possibly used as diagnostic markers to link diabetes and the incidence of breast cancer or even a specific kind of breast cancer.…”

New York Esophageal Squamous Cell Carcinoma-1 and Cancer Immunotherapy

“…[8]. A higher false-negative rate is anticipated to occur in tissue microarray (TMA)-based analyses due to sampling error, given that CTA expression in tumors is often focal [45].…”

“…Humoral response in 2/26 (7.6%) [94] Primary breast cancer 14/164 (8.5%)/TMA/ B9.8.1.1 [45] Primary invasive 21/140 (15%)/TMA (IHC)/E978 [48] Invasive breast carcinoma ER-positive tumors 2/50 (4%)/IHC/E978 [51] ER/PR/HER2 triple- [104] 15/112 (13%)/RT-PCR CD8 + T-cell responses in a subset of patients [105] 12/121 (10%)/RT-PCR 1/12 of mRNA positives (8%)/IHC/E978 Humoral response in 1 mRNA positive/82 (1%)/ELISA [106] Colorectal cancer…”